Traditional therapies, including small-molecule drugs and gene therapies, often face challenges with inefficient tissue targeting, requiring high or repeated dosing that can lead to systemic toxicity, off-target effects, and reduced patient compliance.
Our peptide amphiphile micelle delivery platform is engineered to enable precise and efficient delivery of small molecule drugs and genetic therapeutics while reducing systemic toxicity. By improving biodistribution and tissue-specific targeting, we aim to unlock the full therapeutic potential of next-generation medicines.
Engineered for precise tissue-specific delivery to improve therapeutic efficacy while reducing off-target exposure and systemic toxicity.
Deliver therapeutic agents directly to cellular drivers, mitigating disease.
A versatile platform compatible with small molecules and RNA therapeutics, enabling adaptable and personalized treatment strategies.
Preclinical studies demonstrate strong tolerability and safety across multiple animal models.
